Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Roger Echols"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/e49019df00714f81842572828f30dc15
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 8 (2021)
Background: The APEKS-cUTI study demonstrated the non-inferiority of cefiderocol to imipenem−cilastatin in the primary endpoint of the composite of clinical and microbiological outcome in patients with complicated urinary tract infections (cUTIs).
Externí odkaz:
https://doaj.org/article/d3f3b4385cc24a1e89e68c28a8f0a782
Autor:
Christian M Gill, Debora Santini, Miki Takemura, Christopher Longshaw, Yoshinori Yamano, Roger Echols, David P Nicolau
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:983-990
Objective Evaluate the in vivo efficacy and resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam and meropenem using human-simulated regimens (HSR) in the murine infection model. Methods In total, 15 cl
Publikováno v:
The Journal of Clinical Pharmacology. 62:670-680
Cefiderocol is a siderophore cephalosporin for the treatment of infections caused by Gram-negative bacteria including carbapenem-resistant strains. The aim of this study was to develop an intrapulmonary pharmacokinetic model of cefiderocol and assess
Publikováno v:
Infectious Diseases and Therapy. 11:853-870
A post hoc, descriptive analysis of three prospective, randomised, controlled clinical studies investigating cefiderocol in gram-negative bacterial infections was conducted to assess its efficacy in patients with baseline bacteraemia.Data from APEKS-
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 41:467-476
Critically ill patients often present with low serum iron levels or anemia. We evaluated the impact of iron levels and iron homeostasis on the efficacy and safety of cefiderocol, an iron-chelator siderophore cephalosporin, in patients with nosocomial
Autor:
Thomas P. Lodise, Matteo Bassetti, Ricard Ferrer, Thierry Naas, Yoshihito Niki, David L. Paterson, Markus Zeitlinger, Roger Echols
Publikováno v:
Scientia
Pathogen-focused, randomized, controlled trials (PF-RCT) are important in the fight against carbapenem-resistant (CR) Gram-negative infections. Some recently approved antibiotics and older generic antibiotics with activity against CR Gram-negative ba
Publikováno v:
Infectious Diseases and Therapy
Introduction Colistin is used to treat severe antibiotic-resistant Gram-negative infections (GNIs). With the rise of antibiotic resistance, colistin has been used increasingly as a ‘last-line’ therapy for multidrug-resistant GNIs. We evaluated th
Autor:
Frank H Kung, Sean Nguyen, Christine M Slover, Dee Shortridge, Jennifer M Streit, Roger Echols, Miki Takemura, Yoshinori Yamano
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cefiderocol (CFDC) is a siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including multidrug-resistant organisms. GN bacteria such as Enterobacterales (ENT), Pseudomonas aeruginosa (PsA), Acinet
Autor:
Miki Takemura, Dee Shortridge, Christine M Slover, Christopher M Longshaw, Roger Echols, Yoshinori Yamano
Publikováno v:
Open Forum Infectious Diseases. 9
Background Infections caused by Achromobacter spp. and Burkholderia spp. have limited clinical treatment options due to the intrinsic resistance of these non-fermenters to several antimicrobial agents. These pathogens are known to cause severe nosoco